CLDN18 and gastric cancer: The KEYNOTE-859 and SPOTLIGHT trials, which use ICIs and the monoclonal antibody zolbetuximab to target CLDN18.2, respectively, address an unmet need for additional targeted therapies for patients with previously untreated, HER2-negative, unresectable, or metastatic GC [18].